These diverse observations highlight potential variations in the involvement of SLC38A2 across different pathological subtypes of breast cancer and at various treatment stages, underscoring the need to consider the heterogeneity when targeting SLC38A2 for therapeutic interventions in breast cancer. Here, SLC38A2 is linked to breast cancer.